By George Glover
Eli Lilly stock was soaring Thursday after the pharmaceutical company said it had successfully completed a trial of a new weight-loss pill.
Shares jumped 11% to $817 in premarket trading. Futures tracking the benchmark S&P 500 were up 0.5%.
The surge came after Mounjaro and Zepbound developer Lilly said it had completed a Phase 3 trial for its orforglipron pill. The trial showed that the pill is safe to a level comparable with injectable weight-loss drugs.
Write to George Glover at george.glover@dowjones.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 17, 2025 07:24 ET (11:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.